Cargando…
Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study
BACKGROUND: Solid organ transplant (SOT) recipients are at risk for severe coronavirus disease 2019 (COVID-19), despite vaccination. Our study aimed to elucidate COVID-19 vaccine immunogenicity and evaluate adverse events such as hospitalization, rejection, and breakthrough infection in a SOT cohort...
Autores principales: | Kabbani, Dima, Yotis, Demitra M, Ferreira, Victor H, Shalhoub, Sarah, Belga, Sara, Tyagi, Varalika, Ierullo, Matthew, Kulasingam, Vathany, Hébert, Marie-Josée, West, Lori, Delisle, Jean-Sébastien, Racine, Normand, De Serres, Sacha A, Cardinal, Héloïse, Dieudé, Mélanie, Humar, Atul, Kumar, Deepali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199121/ https://www.ncbi.nlm.nih.gov/pubmed/37213422 http://dx.doi.org/10.1093/ofid/ofad200 |
Ejemplares similares
-
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
por: Kimura, Muneyoshi, et al.
Publicado: (2022) -
Endothelial Dysfunction in Kidney Transplantation
por: Cardinal, Héloïse, et al.
Publicado: (2018) -
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
por: Hall, Victoria G., et al.
Publicado: (2021) -
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023) -
2646. Incidence of Myelosuppression Related to Valganciclovir Prophylaxis in Solid-Organ Transplant Recipients at High Risk of CMV Disease
por: Belga, Sara, et al.
Publicado: (2019)